PentaBind

🌟 Meet Our Newest Team Member at PentaBind! 🌟 We’re excited to welcome Evita Otigbah, PhD to PentaBind as our Scientist II! Evita is a proud alumnus of Kings College London, where she completed her BSc and MRC-funded PhD in Biochemistry, Molecular and Cell Biology. There isn’t a lot Evita hasn’t achieved in the lab… she brings in a wealth of academic and industry expertise that includes structural biology, cell culture, protein expression, GMP manufacturing, oligo chemistry, DNA sequencing, microfluidics, high-throughput screening of drug treatments, and more. Outside of the lab she has worked on several patents related to the production of nucleic acids. When she isn’t lifting pipettes, she is lifting weight plates. Evita recently secured a top 10 spot in the IPF World Powerlifting Championships. Wow! Incase this wasn’t enough, she is also studying for an MSc in Bioinformatics where her project is focused on the molecular modelling of protein-drug interactions. At PentaBind, Evita will be driving and integrating several aptamer discovery pipelines into our AI-first platform; hunting for aptamers that will help treat patients that currently have no option. Join us in welcoming Evita to the team! #PentaBind #aptamer #therapeutics #ai #platform #scientist #drugdiscovery #selex #ngs #automation

🚀 A Review of PentaBind’s New Service: Optimised SELEX Libraries! 🚀 PentaBind provides optimised and customised aptamer libraries for your SELEX pipeline. This new offering is designed to enhance the efficiency and effectiveness of your SELEX experiments, significantly reducing search space and boosting your discovery rate. What We Offer: Our Optimised SELEX Libraries service provides AI-optimised, customised aptamer libraries tailored to your specific needs. This service is ideal for organisations with in-house SELEX capabilities. 🧬✨ Key Features: 💡Significantly reduced search space 🎯Enhanced SELEX efficiency 📈Discovery of up to 300 times more candidates By leveraging our advanced AI technology, you can maximise the success of your SELEX experiments, uncovering a vast number of high-potential aptamers with greater efficiency. View Demo Report and Arrange a call with us to learn more https://lnkd.in/d5m4C7TF. Discover how our Optimised SELEX Libraries service can revolutionise your research and development projects. Embrace the future of aptamer technology with PentaBind.com. #AI #Biotechnology #Research #Innovation #PentaBind #tech #techbio #startups #drugdiscovery #aptamer #aptamers #oligos #generativeai #biotech #community #pharma #artificialintelligence #venturecapital

🚀 A Review of PentaBind’s New Service: SELEX Analysis! 🚀 PentaBind's advanced AI technology provides a definitive analysis of your SELEX experiments, ensuring no high-performance aptamers are overlooked. What We Offer: Our SELEX Analysis service is specifically designed for organisations with aptamer SELEX data. This service uses AI to confirm the success of your SELEX experiment by analysing the data you submit, identifying SELEX enrichment and SELEX biased sequences. 🧬🔍 Key Features: - Accurate identification of SELEX enrichment 💡 - Detection of SELEX biased sequences 🎯 - Comprehensive analysis of SELEX data 📈 Traditional bioinformatics using frequency/abundance analysis might be missing high-performance aptamers in your SELEX data. PentaBind's SELEX Analysis ensures that you uncover the best-performing sequences. We offer a free trial service to get you started, and the paid version provides detailed insights into the top-performing, unique sequences. View Demo Report and Arrange a call with us to learn more https://lnkd.in/d5m4C7TF Discover how our SELEX Analysis service can optimise your research and reveal the full potential of your SELEX experiments. Embrace the future of aptamer technology with PentaBind.com #SELEXAnalysis #AI #Biotechnology #Research #Innovation #PentaBind #AptamerTechnology #tech #techbio #ai #startups #drugdiscovery #aptamers #oligos #generativeai #biotech #community #pharma #artificialintelligence #venturecapital

🚀 A Review of PentaBind’s New Service: Aptamer Design! 🚀 PentaBind's innovative AI technology and wet-laboratory platform can generate de novo aptamers, tailored to your specific needs. What We Offer: Our Aptamer Design service generates a shortlist of de novo aptamers that fit your specific requirements. This service is ideal for applications in diagnostics, therapeutics, bioprocessing, and other aptamer-related fields. 🧬✨ Key Features: - Enhanced binding affinity 💡 - Target specificity 🎯 - Conformational folding 🔄 - Additional critical application-relevant characteristics 📈 PentaBind’s advanced technology integrates unique characteristics beyond the reach of traditional SELEX, ensuring that you receive aptamers designed for high performance and suitability for your specific applications. View Demo Report and Arrange a call with us to learn more https://lnkd.in/d5m4C7TF. Discover how our Aptamer Design service can revolutionise your research and development projects. Embrace the future of aptamer technology with PentaBind.com #AptamerDesign #AI #Biotechnology #Research #Innovation #PentaBind #AptamerTechnology #tech #techbio #ai #startups #drugdiscovery #aptamer #aptamers #oligos #generativeai #biotech #community #pharma #artificialintelligence #venturecapital

🚀 A Review of PentaBind’s New Service: Aptamer Evaluation! 🚀 PentaBind has recently expanded the application of AI in the aptamer field, unlocking new possibilities for research and development. Let’s explore what our innovative new service offers. Our Aptamer Evaluation service is designed to quickly assess the performance of any existing aptamer within just 48 hours – ideal for testing aptamers from academic publications or catalogues. 🧬 What We Offer: Use AI to swiftly test the performance of an aptamer from your laboratory or from an academic paper. Receive comprehensive results within 48 hours, including insights into: - Binding affinity 💡 - Target variant specificity 🎯 - Isoform specificity 🎯 - Target avoidance 📉 - SELEX bias 📈 PentaBind provides a performance evaluation of any aptamer you submit to us. This ensures swift and accurate insights for your research and development needs, saving valuable wet-laboratory time and costs. With our detailed analysis, you can make informed decisions about your aptamer projects with confidence. View Demo Report and arrange a call with us to learn more from https://lnkd.in/d5m4C7TF. Discover how our Aptamer Evaluation service can accelerate your research and bring unprecedented accuracy to your work. Embrace the future of aptamer technology with PentaBind.com #AptamerEvaluation #AI #Biotechnology #Research #Innovation #PentaBind #AptamerTechnology #techbio #ai #startups #drugdiscovery #aptamers #oligos #generativeai #biotech #community #pharma #artificialintelligence #venturecapital

🚀 Calling Science Startup Founders! 🚀 Our friend KQ Labs is looking for exciting startups to join KQ Labs Cohort 7, kicking off in January 2025! KQ Labs is on the lookout for early-stage UK-based startups in data science, software, and biomedical research. The programme offers a fantastic opportunity to grow your startup and will wrap up with a Demo Day in Spring 2025. At PentaBind, we are proud to support this initiative and encourage innovative startups to take advantage of this opportunity. More details on the programme and the application link can be found here. https://lnkd.in/eHteqjki. The deadline is 12 August. Don’t miss out on this incredible opportunity to accelerate your startup’s growth! #Startups #DataScience #Software #BiomedicalResearch #KQLabs #Entrepreneurship #Innovation #DemoDay #PentaBind https://lnkd.in/d5jM9xVh

🔬 Exploring the Latest Trends in the Aptamer Industry 🌟 The aptamer industry is rapidly evolving, driven by innovative research and technological advancements. At PentaBind, we’re at the forefront of these exciting developments. Here are some key trends shaping the future of aptamer technology: 🧬 AI-Powered Aptamer Design: Leveraging artificial intelligence to enhance the design and evaluation of aptamers is revolutionising the field. AI allows for faster, more accurate identification of high-performance aptamers, reducing the time and cost of development. 🩺 Diagnostic Applications: Aptamers are becoming increasingly popular in diagnostic applications due to their high specificity and binding affinity. They are being used to develop sensitive and rapid diagnostic tests for a range of diseases, including COVID-19. 💊 Therapeutic Potential: The therapeutic use of aptamers is gaining traction, with several aptamer-based drugs advancing through clinical trials. Aptamers offer a promising alternative to antibodies, with advantages such as lower immunogenicity and easier production. 🔍 SELEX Optimisation: Advances in SELEX (Systematic Evolution of Ligands by Exponential Enrichment) are improving the efficiency of aptamer selection. Optimised SELEX processes, combined with AI, are identifying high-affinity aptamers more effectively. 🔗 Bioconjugation Techniques: New bioconjugation methods are enabling the functionalisation of aptamers for targeted drug delivery and molecular imaging. These techniques enhance the versatility and application range of aptamers. At PentaBind, we are committed to staying ahead of these trends and incorporating the latest innovations into our services. Discover how our AI-powered aptamer solutions can transform your research and development projects at PentaBind.com. #tech #techbio #ai #startups #drugdiscovery #aptamers #oligos #generativeai #biotech #community #pharma #artificialintelligence #venturecapital

🎉 PentaBind is delighted to have been shortlisted as DeepTech Investment of the Year by UK Business Angels Association, an award sponsored by Royal Academy of Engineering! 🎉 Thanks to all of PentaBind's investors, in particular Twin Path Ventures, who celebrated with us and were nominated themselves for an award by UK Business Angels Association! #tech #techbio #ai #startups #drugdiscovery #aptamers #generativeai #biotech #artificialintelligence #venturecapital #angelinvesting #angels

🎉 Exciting News from PentaBind! 🎉 We are pleased to announce PentaBind's four new AI-powered aptamer services, offering unprecedented solutions for the aptamer industry 🚀: 🩺 Aptamer Evaluation: Use AI to quickly evaluate the performance of an existing aptamer e.g. from a catalogue or from an academic paper. Receive detailed performance evaluations within <48 hours, including insights on binding affinity, specificity, SELEX bias, and more. ✨ Aptamer Design: Generate de novo aptamers with PentaBind's AI and wet-laboratory platform. PentaBind understands that aptamer commercialisation projects need aptamers with more characteristics than binding affinity alone. This is why we built our platform to design high-performing aptamers with enhanced binding, specificity, conformational folding, and more. Services specifically for organisations with aptamer SELEX data: 🔍 SELEX Analysis: Use AI to definitively confirm if your SELEX experiment had successful enrichment and which sequences performed best. Traditional bioinformatics using frequency/abundance analysis might be missing high-performance aptamers in your SELEX data. 🧬 Optimised SELEX Libraries: Receive AI-optimised, customised aptamer libraries to use within your SELEX experiment to significantly reduce search space and boost your SELEX efficiency, discovering up to 300 times more candidates. 🤝 Share this post with anyone you think may find these services valuable! Discover how PentaBind can revolutionise your research: https://lnkd.in/d5m4C7TF Schedule a call with PentaBind to learn more: https://lnkd.in/d2JggX36 #AptamerDesign #Biotechnology #AI #ResearchInnovation #PentaBind #tech #techbio #startups #drugdiscovery #aptamers #oligos #antibody #antibodies #generativeai #biotech #community #pharma #artificialintelligence #venturecapital

🎉 Celebrating International Day of Women in Engineering! 🎉 On June 23rd, we honour the incredible contributions of women engineers who are driving innovation and breaking barriers. Today, we spotlight Dr. Frances Arnold, a pioneering figure in AI and biotechnology. As the first American woman to win the Nobel Prize in Chemistry, Frances has revolutionised protein engineering. Her work in directed evolution has led to the development of enzymes used in sustainable biofuels and medical applications. Frances' innovative use of AI and machine learning in biocatalysis is transforming the future of biotech. Join us in celebrating the brilliance and impact of women in engineering! More aptamer news at Pentabind.com🌟 #PentaBind #WomenInEngineering #AI #Biotech #Innovation #STEM #InternationalWomenInEngineeringDay #tech #techbio #drugdiscovery #aptamers #oligos #generativeai #biotech #community #pharma #artificialintelligence #venturecapital #startups